BioWorld https://www.bioworld.com/rss en-us Regulatory actions for May 7, 2026 http://www.bioworld.com/articles/730977 Thu, 07 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730977-regulatory-actions-for-may-7-2026 Other news to note for May 7, 2026 http://www.bioworld.com/articles/730976 Thu, 07 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730976-other-news-to-note-for-may-7-2026 In the clinic for May 7, 2026 http://www.bioworld.com/articles/730975 Thu, 07 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730975-in-the-clinic-for-may-7-2026 Financings for May 7, 2026 http://www.bioworld.com/articles/730974 Thu, 07 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730974-financings-for-may-7-2026 Appointments and advancements for May 7, 2026 http://www.bioworld.com/articles/730973 Thu, 07 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730973-appointments-and-advancements-for-may-7-2026 Atara rises on new FDA pathway for Ebvallo resubmission http://www.bioworld.com/articles/730972 Thu, 07 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730972-atara-rises-on-new-fda-pathway-for-ebvallo-resubmission Moderna, Vir among early 2026 top infectious disease gainers BioWorld Infectious Disease Index (BIDI), saw their collective shares roughly follow the path of broader markets like the Nasdaq Biotechnology Index (NBI) and the Dow Jones Industrial Average (DJIA) in early 2026. The BIDI ended April up 3.8%, followed by the DJIA with a 3.31% gain and 2.73% for the NBI, following a similar pattern to 2025.]]> http://www.bioworld.com/articles/730971 Thu, 07 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730971-moderna-vir-among-early-2026-top-infectious-disease-gainers Viruses FDA slowdown on Tzield sBLA underlines CNPV questions http://www.bioworld.com/articles/730970 Thu, 07 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730970-fda-slowdown-on-tzield-sbla-underlines-cnpv-questions FDA logo on textured paper Credit: Araki Illustrations - stock.adobe.com Hantavirus is ‘sentinel’ more than acute pandemic threat MV Honduz, the ship currently heading to the Canary Islands with its remaining passengers plus assorted medical, WHO and European Center for Disease Prevention and Control staff, is the 2026 version of the Diamond Princess.]]> http://www.bioworld.com/articles/730969 Thu, 07 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730969-hantavirus-is-sentinel-more-than-acute-pandemic-threat Close up of bow of cruise ship Phase II Engene trouble: NMIBC detalimogene data throttle stock http://www.bioworld.com/articles/730968 Thu, 07 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730968-phase-ii-engene-trouble-nmibc-detalimogene-data-throttle-stock Bladder Entrada sinks on mixed DMD data with ENTR-601-44 http://www.bioworld.com/articles/730967 Thu, 07 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730967-entrada-sinks-on-mixed-dmd-data-with-entr-601-44 Red arrow pointing downward on a stock market ticker Roche to acquire Pathai for up to $1.05B http://www.bioworld.com/articles/730966 Thu, 07 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730966-roche-to-acquire-pathai-for-up-to-105b Roche building Credit: F. Hoffmann-La Roche Ltd. Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst http://www.bioworld.com/articles/730965 Thu, 07 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730965-italys-angelini-pays-41b-cash-for-rare-disease-specialist-catalyst Neurology illustration US FDA tries out 1-day inspections http://www.bioworld.com/articles/730852 Thu, 07 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730852-us-fda-tries-out-1-day-inspections Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst http://www.bioworld.com/articles/730978 Thu, 07 May 2026 11:00:00 -0400 https://www.bioworld.com/articles/730978-italys-angelini-pays-41b-cash-for-rare-disease-specialist-catalyst First measles treatment advances as vaccination rates drop http://www.bioworld.com/articles/730929 Thu, 07 May 2026 11:00:00 -0400 https://www.bioworld.com/articles/730929-first-measles-treatment-advances-as-vaccination-rates-drop Rendering of a key measles protein targeted by neutralizing human antibodies This rendering shows a key measles protein (white) targeted by neutralizing human antibodies (pink). Credit: Dawid Zyla, La Jolla Institute for Immunology Today's news in brief http://www.bioworld.com/articles/432891 Thu, 07 May 2026 10:00:00 -0400 https://www.bioworld.com/articles/432891-todays-news-in-brief Regulatory actions for May 6, 2026 http://www.bioworld.com/articles/730873 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730873-regulatory-actions-for-may-6-2026 Other news to note for May 6, 2026 http://www.bioworld.com/articles/730872 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730872-other-news-to-note-for-may-6-2026 In the clinic for May 6, 2026 http://www.bioworld.com/articles/730871 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730871-in-the-clinic-for-may-6-2026 Financings for May 6, 2026 http://www.bioworld.com/articles/730870 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730870-financings-for-may-6-2026 Appointments and advancements for May 6, 2026 http://www.bioworld.com/articles/730869 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730869-appointments-and-advancements-for-may-6-2026 China med-tech raises: Star Sports’ $105M IPO; Cofoe nabs $133M http://www.bioworld.com/articles/730868 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730868-china-med-tech-raises-star-sports-105m-ipo-cofoe-nabs-133m ​Star Sports Medicine HKEX IPO ceremony Star Sports Medicine's IPO ceremony on May 5. Credit: HKEX; x.com – @HKEXGroup Multiple appearances on Priority Watch List leading to action? http://www.bioworld.com/articles/730867 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730867-multiple-appearances-on-priority-watch-list-leading-to-action Magnifying glass on wooden table Kailera's record IPO headlines strong April for biopharma financings http://www.bioworld.com/articles/730866 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730866-kaileras-record-ipo-headlines-strong-april-for-biopharma-financings Financial markets rebound illustration Swiss Biotech reports record private investment, employment in 2025 http://www.bioworld.com/articles/730865 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730865-swiss-biotech-reports-record-private-investment-employment-in-2025 Swiss currency GSK licenses siRNA asset in $1B deal for Siranbio http://www.bioworld.com/articles/730864 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730864-gsk-licenses-sirna-asset-in-1b-deal-for-siranbio Illustration of siRNA structure Resmed boosts sleep health portfolio with Noctrix buy http://www.bioworld.com/articles/730863 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730863-resmed-boosts-sleep-health-portfolio-with-noctrix-buy Noctrix Health Nidra system Nidra, a wearable neuromodulation device for restless legs syndrome. Credit: Noctrix Health Inc. Bayer buying Perfuse for $300M up front in potential $2.45B deal http://www.bioworld.com/articles/730862 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730862-bayer-buying-perfuse-for-300m-up-front-in-potential-245b-deal Eye and financial charts Abdakibart phase II graded, puts Avalo in HS upper class http://www.bioworld.com/articles/730861 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730861-abdakibart-phase-ii-graded-puts-avalo-in-hs-upper-class Hand held near armpit